4-(Methylsulfonyl)phenylacetic Acid CAS 90536-66-6 Ubunyulu >99.5% (HPLC) Etoricoxib Intermediate Factory
UMvelisi oPhambili kunye noMboneleli, abaPhakathi be-Etoricoxib
Etoricoxib API CAS 202409-33-4
4-(Methylthio)Phenylacetic Acid CAS 16188-55-9
4-(Methylsulfonyl)Phenylacetic Acid CAS 90536-66-6
Please contact: alvin@ruifuchem.com
| Igama leMchiza | 4-(Methylsulfonyl)phenylacetic Acid |
| Izithethantonye | I-4-Methylsulphonylphenylacetic Acid;4-(Methanesulfonyl)phenylacetic Acid;(4-Methanesulfonylphenyl)acetic Acid;I-4-Methylsulfonyl Phenyl Acetic Acid;2-(4-(Methylsulfonyl)phenyl)acetic Acid;[p-(Methylsulfonyl)phenyl]-Acetic Acid;I-4-Mesylphenylacetic Acid |
| Inombolo yeCAS | 90536-66-6 |
| Inombolo yeCAT | RF-PI1182 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C9H10O4S |
| Ubunzima beMolekyuli | 214.24 |
| Indawo yokunyibilika | 136.0 ukuya 140.0℃ |
| Ukuxinana | 1.35 |
| Ukunyibilika | Inyibilika kwiMethanol |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo oqinileyo oMhlophe ukuya kokuMhlophe |
| Ubunyulu / Indlela yokuHlalutya | >99.5% (HPLC) |
| Indawo yokunyibilika | 136.0 ukuya 140.0℃ |
| Ukufuma (KF) | <0.50% |
| Ukungcola Okukodwa Okukhulu | <0.30% |
| Ukungcola ngokupheleleyo | <0.50% |
| I-Infrared Spectrum | Iyahambelana noLwakhiwo |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Umbindi we-Etoricoxib (CAS: 202409-33-4) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-4-(Methylsulfonyl) phenylacetic Acid (CAS: 90536-66-6) iphakathi kwe-Etoricoxib (CAS: 202409-33-4).I-Etoricoxib luhlobo olukhethiweyo kakhulu lwe-cyclooxygenase-2 (COX-2) inhibitors eyenziwe yinkampani yakwaMerck.I-Etoricoxib isetyenziswa ngokubanzi kunyango lwe-osteoarthritis (OA), isifo samathambo, isifo samathambo, i-ankylosing spondylitis, iintlungu ezinganyangekiyo ezisezantsi, i-acute gouty arthritis, i-dysmenorrhea ephambili kunye neentlungu zasemva kokuhlinzwa, kunye nezinye izifo.I-Etoricoxib, i-COX-2 inhibitor ekhethiweyo, ineempembelelo ezichasayo, i-analgesic kunye ne-antipyretic, ifanelekile unyango lweempawu kunye neempawu ze-osteoarthritis enzima kunye engapheliyo, kunye ne-acute gouty arthritis.I-Etoricoxib ixutywa ngokukhawuleza, kunye ne-bioavailability yomlomo ye-80 ukuya kwi-100%, kwaye ifikelela kwi-plasma concentrations ephezulu kwi-1 kwiiyure ze-2 emva kwe-dosing.Ukutya kunciphisa izinga lokufunxa kodwa akunampembelelo kubungakanani bokufunxa.Ibonisa ixesha elide lokuphelisa isiqingatha sobomi malunga neeyure ezingama-22, ebonisa i-pharmacokinetics ye-plasma ehambelanayo ngaphandle kokuqokelela ngexesha le-dosing eninzi.
